Welcome to our dedicated page for ALLURION TECHNOLOGIES news (Ticker: ALUR), a resource for investors and traders seeking the latest updates and insights on ALLURION TECHNOLOGIES stock.
Allurion Technologies, Inc. develops a weight-loss platform centered on the Allurion Program, which combines the FDA PMA approved Allurion Gastric Balloon System featuring the Allurion Smart Capsule with a Virtual Care Suite that includes the Allurion Mobile App, Iris AI, Allurion Insights and the Allurion Connected Scale.
Company news centers on U.S. commercialization of the Allurion Smart Capsule, FDA regulatory status, provider training and commercial account onboarding, obesity-care partnerships and use of the program alongside GLP-1 therapies. Updates also cover preliminary operating results, balance-sheet and warrant-related capital actions, and listing-compliance matters involving Allurion common stock and warrants.
Allurion Technologies has announced the pricing of a $20 million public offering and concurrent private placement. The company will issue 14,406,508 shares and an equal number of warrants at $1.20 per share, generating $17.3 million in gross proceeds. An additional $2.7 million will come from the sale of Series A convertible preferred stock and private placement warrants to RTW Investments. The total expected gross proceeds from these offerings are $20 million. The funds will support clinical trials, commercial sales, R&D, and general corporate purposes. The offerings are anticipated to close by July 1, 2024, pending customary conditions.
Allurion Technologies (NYSE: ALUR) has launched a public offering of up to $20 million in common stock and warrants. The offering is managed by Jefferies and TD Cowen, with Roth Capital Partners co-managing. Allurion plans to use the proceeds for clinical trials, commercial sales, R&D, and general corporate purposes. Additionally, RTW Investments has shown interest in purchasing up to $3 million of the securities, potentially through a concurrent private placement of Series A convertible preferred stock. The offering is contingent on SEC registration approval.
Allurion Technologies (NYSE: ALUR) published new data showing that patients on the Allurion Program gained an average of 5.6% lean mass while losing 14% body weight over four months. The study included 571 patients tracked using the Allurion App, Connected Scale, and Health Tracker, supported by the AI-driven Allurion Virtual Care Suite. On average, patients reduced their weight from 97.9kg to 84.0kg and increased lean mass from 49.8kg to 52.6kg. Higher activity patients achieved a greater weight loss (15.6kg) and more significant lean mass gains (2.8kg) compared to lower activity patients. The body fat percentage also decreased from 32.7% to 27.9%. This study contrasts with GLP-1 therapy results, which typically show lean mass loss ranging from 3-11%, highlighting the potential of real-time body composition monitoring and personalized recommendations.
Allurion Technologies (NYSE: ALUR) presented new data at the American Society for Metabolic and Bariatric Surgery Annual Meeting, showing a 22.1% weight loss at one year with its Allurion Balloon, surpassing the 15.4-16.2% weight loss achieved by 12-month endoscopic balloons. The study involved 121 patients across 11 obesity centers. Additional presentations highlighted the Allurion Balloon's low intolerance rate (1-3%) compared to other balloons (14.4%), and a 10-fold decrease in serious adverse events. The AI-powered Coach Iris received high satisfaction scores, with 84% for Fidelity, 79% for Accuracy, 89% for Safety, and 95% for Tone. Other topics included digital tracking of hunger and fullness.
Allurion Technologies (NYSE: ALUR) has appointed Ojas A. Buch as Chief Operating Officer, effective June 3, 2024. Buch will oversee Research and Development, Manufacturing, Operations, Quality and Regulatory, and Business Development and Innovation functions. He brings 25 years of experience in the healthcare industry, having held leadership roles at GE Healthcare, St Jude Medical (Abbott), CareFusion (Vyaire), Philips, and PENTAX Medical – Americas. His appointment aims to help Allurion achieve significant milestones and scale sustainably. Dr. Shantanu Gaur, Allurion’s Founder and CEO, emphasized Buch's strategic mindset and leadership skills as critical to Allurion's growth and innovation in the weight loss solutions market.
Allurion Technologies (NYSE: ALUR) has expanded its AI-powered weight loss coach, Coach Iris, to support patients on GLP-1s and other anti-obesity medications. This enhancement provides 24/7 personalized coaching on treatment duration, side effects, and lifestyle modifications. In addition, the company announced its first commercial agreements for its Virtual Care Suite (VCS) in the U.S.
The VCS integrates remote patient monitoring, predictive analytics, telehealth, and care team collaboration, and is designed for healthcare providers offering various weight loss therapies. Medical professionals like Dr. Christopher McGowan and Dr. Alexander Shapsis have adopted VCS, praising its ability to deliver personalized care and improve patient engagement.
According to Blue Cross Blue Shield, a substantial portion of patients discontinue GLP-1s prematurely, underscoring the need for better patient management. An Allurion study found that the VCS improved patient accountability, practice efficiency, and engagement.
Allurion Technologies (NYSE: ALUR) has announced its participation in two major investor conferences: the Jefferies Global Healthcare Conference and the Sidoti Small Cap Virtual Conference in June 2024.
The company aims to discuss its strategic initiatives, latest financial performance, and long-term growth plans at these events.
Allurion Technologies (NYSE: ALUR) announced three presentations at the European Congress on Obesity (ECO) held from May 12-15, 2024, in Venice, Italy. The presentations highlighted data from a study involving 712 patients across six obesity centers, demonstrating an average total body weight loss (TBWL) of 14.1% in four months, with 70% of the weight loss from fat mass and only 30% from lean body mass. The Allurion Program, which includes the Allurion Balloon and Virtual Care Suite, aims to preserve lean body mass during weight loss. Additionally, previous studies showed that more intensive programs led to 100% fat mass-derived weight loss without muscle mass loss. The presentations also covered behavior change coaching and the positive impact of GLP-1s on the program.
Allurion Technologies (NYSE: ALUR) announced its Q1 2024 financial results with a revenue of $9.4 million, a 14% increase from Q4 2023 but a decrease from $14.1 million in Q1 2023. Procedural volume rose 12% year-over-year and 22% sequentially. Cash burn decreased to $8.4 million from $22 million in Q4 2023. Notable developments include treating the first NHS patient with the Allurion Balloon, launching the VCS digital platform in the U.S., and securing $48 million in financing. Operating expenses were reduced significantly, but a year-over-year revenue decline and lower gross profit margins were noted.
Allurion Technologies, Inc. (NYSE: ALUR) announced three scientific presentations at IFSO-European Chapter 2024, highlighting 80% sustained weight loss at three years with the Allurion Program and successful outcomes of an AI-powered conversational agent for obesity treatment. The data showcased positive long-term weight maintenance results and patients' healthier eating habits post-program. Additionally, the innovative AI-powered weight loss coach, Coach Iris, received positive feedback for its personalized, trustworthy, and empathetic approach.